Your browser doesn't support javascript.
loading
Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination.
Wang, Fuzhen; Huang, Baoying; Lv, Huakun; Feng, Lizhong; Ren, Weihong; Wang, Xiaoqi; Tang, Lin; Liu, Qianqian; Wu, Dan; Zheng, Hui; An, Zhijie; Deng, Yao; Zhao, Li; Ye, Fei; Wang, Wenling; Zhang, Hangjie; Chang, Shaoying; Liao, Yuting; Chen, Fengyang; Rodewald, Lance E; Gao, George F; Yin, Zundong; Tan, Wenjie.
Afiliação
  • Wang F; National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Huang B; National Health Commission (NHC) Key Laboratory of Biosafety, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Lv H; Immunization Program Institute, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
  • Feng L; Immunization Program Institute, Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China.
  • Ren W; Xingtai Center for Disease Control and Prevention, Xingtai, China.
  • Wang X; National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Tang L; National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Liu Q; National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Wu D; National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Zheng H; National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
  • An Z; National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Deng Y; National Health Commission (NHC) Key Laboratory of Biosafety, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Zhao L; National Health Commission (NHC) Key Laboratory of Biosafety, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Ye F; National Health Commission (NHC) Key Laboratory of Biosafety, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Wang W; National Health Commission (NHC) Key Laboratory of Biosafety, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Zhang H; Immunization Program Institute, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
  • Chang S; Immunization Program Institute, Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China.
  • Liao Y; School of Public Health, Xiamen University, Xiamen, China.
  • Chen F; Xingtai Center for Disease Control and Prevention, Xingtai, China.
  • Rodewald LE; National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Gao GF; Chinese Center for Disease Control and Prevention, Beijing, China.
  • Yin Z; National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Tan W; National Health Commission (NHC) Key Laboratory of Biosafety, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Front Immunol ; 13: 967051, 2022.
Article em En | MEDLINE | ID: mdl-36159863
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article